Information Provided By:
Fly News Breaks for September 6, 2017
CLVS
Sep 6, 2017 | 07:46 EDT
JPMorgan analyst Cory Kasimov reiterates an Overweight rating on shares of Clovis Oncology ahead of the full ARIEL 3 data on Friday at ESMO in Madrid. Since Clovis already provided a significant amount of detail, the analyst expects the full data set to be "robust, albeit somewhat incremental overall." Kasimov continues to see "significant strategic value" in Clovis and keeps a $111 price target on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.